Steven Tjoe > Goodwin > Washington DC, United States > Lawyer Profile
Goodwin Offices
1900 N Street NW
Washington, District of Columbia 20036
United States
- Firm Profile
- Go to...
Steven Tjoe
Position
Partner
Career
Steven Tjoe is a partner in the firm’s Technology and Life Sciences groups and a member of the firm’s Life Sciences Regulatory & Compliance practice. He focuses his practice on product development strategies and regulatory compliance counseling, in particular as related to medical devices, digital health products, in vitro diagnostics, laboratory developed tests, compounded drugs, cell and gene therapies, and other drugs and biologics. Steven advises clients in analyzing premarket pathways, product adverse event risk profiles, product communications and marketing, and GMP compliance. Steven also advises on Hatch-Waxman patent listing and exclusivity issues, is a contributor to Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., and regularly conducts risk analyses for offerings and transactions involving FDA-regulated entities across the medical device, drug, and biologic industries.
Recently, Steven has brought his experience as former regulatory counsel at FDA to help in vitro diagnostic, laboratory developed test, digital health developer, and non-traditional medical device manufacturer clients launch critical diagnostic and therapeutic products in response to the COVID-19 public health emergency.
Education
JD, 2013, Antonin Scalia Law School, George Mason University / MS, 2012, Case Western Reserve University / BA, 2006, Duke University
Lawyer Rankings
United States > Healthcare > Life sciences
(Next Generation Partners)Goodwin’s global practice advises biotech, pharma, and healthcare companies, along with life science venture capital and investment firms. The growing practice supports clients in matters as wide-ranging as regulatory compliance, IP and M&A. The team’s representation of Prime Medicine in its $3.5bn deal with Bristol Myers Squibb evidences its excellence in research collaboration and license agreement matters. The practice is headed by Kingsley Taft, vastly experienced in commercial, financing and capital market transactions, and Mitchell Bloom, who specializes in emerging companies and life sciences investors. Both in Boston, transactional lawyer Robert Puopolo and Marishka DeToy, who focuses on capital markets and corporate matters, are key figures in the practice. In DC, Steven Tjoe focuses on product development strategies and FDA regulatory counseling. Arriving on the Boston-based team from Cooley LLP are Joshua Rottner, venture capital and growth equity funds specialist, and Michael McGrail, focused on medical devices and life sciences. Other key hires include litigation expert Michael Siekman, arriving in Boston from McDermott Will & Emery LLP, M&A specialist Amanda Gill, from Paul, Weiss, Rifkind, Wharton & Garrison LLP, and IP lawyer Carl Morales, from Fenwick & West LLP; the latter two are based in New York.
Lawyer Rankings
- Next Generation Partners United States > Healthcare > Life sciences
- Life sciences United States > Healthcare
Top Tier Firm Rankings
- Industry focus > Cannabis
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Dispute resolution > E-discovery
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Intellectual property > Patents: litigation (full coverage)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- M&A/corporate and commercial > Shareholder activism
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade and national security > Customs, export controls and economic sanctions
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Healthcare > Service providers
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate finance
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Financial services regulation